Vasculitis & polymyalgia rheumatica
Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome
Authors' conclusion
This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Behçet's syndrome who had ulcers despite being on colchicine maintenance therapy.
Study context
- Population
- Patients with BD with at least two active oral and/or one active genital ulcer(s) at enrolmentwith oral ulcers
- Participants
- 8 patients
- Comparison
- Intravenous dusquetide, no concurrent control
- Dusquetiden = 8
- Outcome
- Perceived benefit (reduction in number, duration and pain of oral ulcers)
Methodological detailssingle-arm, comparison to historical placebo groups
- Single-arm
- Comparison to historical placebo groups
Main finding
As reported in the abstract
- Seven of eight participants reported a perceived benefit including reduction in number, duration and pain of oral ulcers
- 7
Further findings
Comparison to historical placebo groups
- Reduction in number of ulcers, time to resolution of ulcers, AUC of ulcer-days, oral pain and baseline quality of life metrics
Safety
- Well-tolerated; no treatment-related AEs and no serious or severe adverse events recorded
Original publication
Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome. Rheumatology (Oxford). Published 16 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →